CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.152
EU - Europa 6.660
AS - Asia 6.010
SA - Sud America 897
Continente sconosciuto - Info sul continente non disponibili 305
AF - Africa 230
OC - Oceania 8
Totale 23.262
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.709
RU - Federazione Russa 3.307
SG - Singapore 2.612
CN - Cina 1.324
IT - Italia 1.180
BR - Brasile 675
VN - Vietnam 607
HK - Hong Kong 565
GB - Regno Unito 479
FR - Francia 354
DE - Germania 335
IE - Irlanda 295
SE - Svezia 261
BD - Bangladesh 226
CA - Canada 216
KR - Corea 176
FI - Finlandia 122
IN - India 114
JP - Giappone 79
AR - Argentina 76
MX - Messico 66
NL - Olanda 61
ES - Italia 54
ID - Indonesia 51
PL - Polonia 47
ZA - Sudafrica 46
NG - Nigeria 41
TR - Turchia 41
BJ - Benin 37
IQ - Iraq 37
TG - Togo 36
CO - Colombia 35
UA - Ucraina 31
VE - Venezuela 31
CR - Costa Rica 30
AT - Austria 28
EC - Ecuador 27
SA - Arabia Saudita 22
PK - Pakistan 21
SV - El Salvador 21
BE - Belgio 19
GT - Guatemala 19
HN - Honduras 19
CL - Cile 18
PH - Filippine 15
JM - Giamaica 14
LT - Lituania 14
MA - Marocco 14
UZ - Uzbekistan 14
IL - Israele 13
PY - Paraguay 13
SC - Seychelles 13
GP - Guadalupe 12
PR - Porto Rico 12
CW - ???statistics.table.value.countryCode.CW??? 11
JO - Giordania 11
MY - Malesia 11
TT - Trinidad e Tobago 11
AZ - Azerbaigian 10
KE - Kenya 9
NI - Nicaragua 9
NO - Norvegia 8
NP - Nepal 8
PE - Perù 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
LB - Libano 7
AU - Australia 6
BG - Bulgaria 6
AL - Albania 5
CZ - Repubblica Ceca 5
EE - Estonia 5
EG - Egitto 5
PT - Portogallo 5
TH - Thailandia 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
KZ - Kazakistan 4
LV - Lettonia 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
ET - Etiopia 3
GH - Ghana 3
GR - Grecia 3
HU - Ungheria 3
LY - Libia 3
QA - Qatar 3
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BN - Brunei Darussalam 2
BZ - Belize 2
CI - Costa d'Avorio 2
DM - Dominica 2
Totale 22.926
Salva come PNG Salva come JPEG
Città #
Singapore 1.340
Ashburn 1.331
San Jose 1.162
Moscow 1.095
Dallas 823
Chandler 604
Hong Kong 554
Council Bluffs 485
New York 379
Verona 363
Beijing 309
The Dalles 308
Dublin 290
Southend 245
Ho Chi Minh City 185
Los Angeles 171
Hanoi 133
Princeton 121
Lawrence 120
Sindelfingen 102
Santa Clara 99
Wilmington 97
Buffalo 95
Milan 89
Jacksonville 84
Munich 79
Redondo Beach 70
London 69
Tokyo 68
São Paulo 67
Rome 65
Columbus 64
Jinan 64
Helsinki 59
Ann Arbor 56
Montreal 55
Nanjing 49
Hebei 46
Woodbridge 46
Shenyang 44
Guangzhou 43
Houston 43
Warsaw 42
Denver 41
Redwood City 41
Boardman 40
Redmond 40
Turku 40
Abuja 38
Brooklyn 38
Orem 38
Cotonou 37
Amsterdam 36
Lomé 35
Atlanta 34
Chennai 34
Chicago 34
Seattle 34
Bologna 33
Phoenix 33
Toronto 32
Zhengzhou 32
Johannesburg 31
Dong Ket 29
Da Nang 28
Haikou 27
Haiphong 27
Nuremberg 27
San Francisco 27
Jakarta 26
McKinney 26
Ningbo 26
Poplar 25
Frankfurt am Main 24
Tianjin 24
Boston 23
Changsha 22
Naples 22
San José 22
Mexico City 21
North Bergen 21
Norwalk 21
Stockholm 21
Cleveland 20
Kent 20
Mumbai 20
Rio de Janeiro 20
San Salvador 19
Taiyuan 18
Guatemala City 17
Brussels 16
Taizhou 16
Turin 16
Falkenstein 15
Hangzhou 15
Philadelphia 15
Brescia 14
Curitiba 14
Florence 14
Shanghai 14
Totale 13.106
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 476
Fatal asthma; is it still an epidemic? 217
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 206
Allergic rhinitis: pharmacotherapy in pregnancy and old age 197
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 194
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 192
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 189
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 188
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 186
Adverse reaction to local anaesthetics: Is it always allergy? 183
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 183
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 182
Asthma and anaphylaxis 177
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 175
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 172
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 168
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 168
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 167
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 165
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 164
Periostin: The bone and beyond 163
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 162
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 162
Allergy and Sexual Behaviours: an Update 161
Allergen-specific immunotherapy and COVID-19: What happened? 160
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 160
Anaphylaxis and intimate behaviour 159
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 159
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 158
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 157
Anxiety and Depression Effects During Drug Provocation Test 157
Biologics and global burden of asthma: A worldwide portrait and a call for action 157
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 156
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 156
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 155
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 154
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 153
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 148
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 148
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 147
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 146
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 146
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 146
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 145
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 145
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 145
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 144
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 144
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 142
COPD prevalence in a north-eastern Italian general population 142
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 137
Diagnosis, management and therapeutic options for eosinophilic esophagitis 132
Uncontrolled Asthma: Unmet Needs in the Management of Patients 132
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 131
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 131
What lies beyond Asthma Control Test: Suggestions for clinical practice 130
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 129
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 129
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 129
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 129
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 129
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 128
Omalizumab management beyond clinical trials: the added value of a network model 128
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 127
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 126
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 126
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 126
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 125
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 125
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 125
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 124
Asthma severity: the patient’s point of view 122
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 122
Targeting eosinophils: severe asthma and beyond 122
Asthma management among different specialists: results from a national Italian survey 122
One year of mepolizumab. Efficacy and safety in real-life in Italy 121
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 121
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 121
Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review 120
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 120
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 120
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma 119
Severe refractory asthma: current treatment options and ongoing research 118
Towards precision medicine: The application of omics technologies in asthma management 118
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 118
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 117
Sex in Respiratory and Skin Allergies 116
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 115
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 115
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 115
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 115
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 115
Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients 114
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 114
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 113
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 112
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 112
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 111
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 111
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker? 111
Totale 14.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.961
article - articoli 92.639
book - libri 0
conference - conferenze 322
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022386 0 0 0 0 15 14 7 50 50 12 58 180
2022/20231.925 145 138 223 221 217 452 42 106 240 12 80 49
2023/20241.481 57 102 122 195 115 345 110 61 19 62 193 100
2024/20253.655 176 214 154 505 134 91 115 346 578 263 302 777
2025/202611.804 809 706 771 1.886 2.981 754 1.059 691 865 549 286 447
2026/20272.339 173 396 418 1.285 67 0 0 0 0 0 0 0
Totale 23.262